scholarly journals Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S)

2017 ◽  
Vol 8 (5) ◽  
pp. 1123-1134 ◽  
Author(s):  
Takuya Awata ◽  
Akira Shimada ◽  
Taro Maruyama ◽  
Yoichi Oikawa ◽  
Nobuyuki Yasukawa ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Pilot Trial ◽  
Dipeptidyl Peptidase ◽  
Open Label ◽  
Dipeptidyl Peptidase 4 ◽  
Randomized Controlled ◽  
Progressive Type ◽  
Dipeptidyl Peptidase 4 Inhibitor

The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes

Life Sciences ◽  
2019 ◽  
Vol 234 ◽  
pp. 116738 ◽  
Author(s):  
Catarina Marques ◽  
Andreia Gonçalves ◽  
Patrícia Manuela Ribeiro Pereira ◽  
Daniela Almeida ◽  
Beatriz Martins ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Type 1 Diabetes ◽  
Rat Model ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Glomerular Lesions

Significant elevation of serum dipeptidyl peptidase-4 activity in young-adult type 1 diabetes

2016 ◽  
Vol 113 ◽  
pp. 135-142 ◽  
Author(s):  
Saeko Osawa ◽  
Dan Kawamori ◽  
Naoto Katakami ◽  
Mitsuyoshi Takahara ◽  
Fumie Sakamoto ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Young Adult ◽  
Dipeptidyl Peptidase ◽  
Significant Elevation ◽  
Adult Type ◽  
Dipeptidyl Peptidase 4
Sign in / Sign up

Export Citation Format

Share Document